JP Morgan Private Wealth Advisors’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

JP Morgan Private Wealth Advisors’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,081	Closed	-$331K	–	1967
2023 Q1	$331K	Buy	3,081 +91	+3%	+$10.5K	﹤0.01%	1642
2022 Q4	$329K	Sell	2,990 -2,615	-47%	-$170K	﹤0.01%	1624
2022 Q3	$331K	Buy	+5,605	New	+$256K	﹤0.01%	1615

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

JP Morgan Private Wealth Advisors's RXDX Position: Q2 2023 in Review

JP Morgan Private Wealth Advisors sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 3,081 shares — an estimated $331K sold.

JP Morgan Private Wealth Advisors first reported a position in RXDX in Q3 2022 and held it in 3 quarters. The position peaked at $331K in Q3 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

JP Morgan Private Wealth Advisors reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
JP Morgan Private Wealth Advisors sold 3,081 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $331K.
JP Morgan Private Wealth Advisors first reported a position in Prometheus Biosciences, Inc. Common Stock in Q3 2022 and held it in 3 quarters.
JP Morgan Private Wealth Advisors's Prometheus Biosciences, Inc. Common Stock position peaked at $331K in Q3 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on JP Morgan Private Wealth Advisors's 13F filing for Q2 2023, filed 28 Jul 2023.